» Articles » PMID: 21568367

Ticagrelor: a Review of Its Use in the Management of Acute Coronary Syndromes

Overview
Journal Drugs
Specialty Pharmacology
Date 2011 May 17
PMID 21568367
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Ticagrelor (Brilique™; Brilinta™), a cyclopentyl-triazolo-pyrimidine antiplatelet agent, is the first oral antagonist of the P2Y(12) receptor to offer reversible receptor binding. It is indicated in the EU for the prevention of atherothrombotic events in adults with acute coronary syndromes (ACS) [unstable angina pectoris, ST-segment elevation myocardial infarction [STEMI] or non-STEMI), including those managed medically or with percutaneous coronary intervention or coronary artery bypass grafting (CABG). Ticagrelor provides selective and reversible inhibition of adenosine diphosphate-induced platelet aggregation, with a faster onset and offset of action than that of clopidogrel, and is effective in the treatment of patients with ACS, with or without ST-segment elevation. In the large, randomized, double-blind, multicentre PLATO trial conducted in this patient population, ticagrelor was more effective than clopidogrel in terms of preventing ischaemic events over 12 months, providing a significantly lower risk of the primary composite endpoint of myocardial infarction, stroke or death from vascular causes, and was associated with an overall mortality benefit. The risk of major bleeding with ticagrelor, including bleeds related to CABG, did not differ from that seen with clopidogrel in this study, although ticagrelor was associated with more non-CABG-related major bleeds and fatal intracranial bleeding, albeit the latter bleeding events were rare. Further long-term and comparative efficacy and tolerability data are required to definitively position ticagrelor with respect to other antiplatelet agents, including prasugrel. However, the clinical data currently available indicate that ticagrelor is a promising option for the treatment of patients with ACS and may be of particular use in those at high risk of ischaemic events or unresponsive to clopidogrel.

Citing Articles

Bioequivalence assessment of two Ticagrelor formulations under fasting condition in healthy Pakistani subjects.

Hashmi N, Jawaid M, Raza Shah M Pak J Med Sci. 2023; 39(6):1647-1651.

PMID: 37936786 PMC: 10626117. DOI: 10.12669/pjms.39.6.8203.


Integrated Pharmacokinetics/Pharmacodynamics Model and Simulation of the Ticagrelor Effect on Patients with Acute Coronary Syndrome.

Liu Z, Liu Y, Mu G, Zhang H, Zhou S, Wang Z Clin Pharmacokinet. 2023; 62(3):435-447.

PMID: 36735213 DOI: 10.1007/s40262-022-01208-0.


Carbohydrate-based drugs launched during 20002021.

Cao X, Du X, Jiao H, An Q, Chen R, Fang P Acta Pharm Sin B. 2022; 12(10):3783-3821.

PMID: 36213536 PMC: 9532563. DOI: 10.1016/j.apsb.2022.05.020.


A Review of the Role of the Antiplatelet Drug Ticagrelor in the Management of Acute Coronary Syndrome, Acute Thrombotic Disease, and Other Diseases.

Tao L, Ren S, Zhang L, Liu W, Zhao Y, Chen C Med Sci Monit. 2022; 28:e935664.

PMID: 35570383 PMC: 9121774. DOI: 10.12659/MSM.935664.


Prolonged ventricular pause associated with ticagrelor use: A case report.

Rahhal A, Aljundi A, Mohamed S, Arif M, Arabi A Clin Case Rep. 2021; 9(10):e05017.

PMID: 34721870 PMC: 8543052. DOI: 10.1002/ccr3.5017.


References
1.
James S, Akerblom A, Cannon C, Emanuelsson H, Husted S, Katus H . Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2009; 157(4):599-605. DOI: 10.1016/j.ahj.2009.01.003. View

2.
Dib C, Hanna E, Abu-Fadel M . A new era for antiplatelet therapy in patients with acute coronary syndrome. Am J Med Sci. 2010; 340(5):407-11. DOI: 10.1097/MAJ.0b013e3181ee5bfb. View

3.
Kowalczyk M, Banach M, Mikhailidis D, Hannam S, Rysz J . Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?. Med Sci Monit. 2009; 15(12):MS24-30. View

4.
Wallentin L, James S, Storey R, Armstrong M, Barratt B, Horrow J . Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010; 376(9749):1320-8. DOI: 10.1016/S0140-6736(10)61274-3. View

5.
Gurbel P, Kereiakes D, Tantry U . Ticagrelor for the treatment of arterial thrombosis. Expert Opin Pharmacother. 2010; 11(13):2251-9. DOI: 10.1517/14656566.2010.511175. View